Zilretta FDA Approval History
Last updated by Judith Stewart, BPharm on May 20, 2021.
FDA Approved: Yes (First approved October 6, 2017)
Brand name: Zilretta
Generic name: triamcinolone acetonide
Dosage form: Extended-Release Injectable Suspension
Company: Flexion Therapeutics, Inc.
Treatment for: Osteoarthritis
Zilretta (triamcinolone acetonide extended-release injectable suspension) is a corticosteroid intra-articular injection indicated for the management of osteoarthritis pain of the knee.
Development timeline for Zilretta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.